Gene-environment interplay in schizopsychotic disorders

Neurotoxicity Research

Volumn 6, Issue 1, 2004, Pages 1-9

  Palomo, Tomas ^a   Archer, Trevor ^b   Kostrzewa, Richard M ^c   Beninger, Richard J ^d  

^a Hospital Universitario   (Spain)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c East Tennessee State University   (United States)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Dopamine; GABA; Genetics; Glutamate; Parvalbumin; PKA; Schizophrenia; Signaling Molecules; Stress

Indexed keywords

ANIMAL; BRAIN LEVEL; ENVIRONMENT; GENETICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN CHEMISTRY; ENVIRONMENT; HUMANS; SCHIZOPHRENIA;

EID: 3242802255     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033291     Document Type: Article

References (84)

1. Akbarian S, JJ Kim, SG Potkin, JO Hagman, A Tafazzoli, WE Bunney Jr and EG Jones (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in pre-frontal cortex of schizophrenics. Arch. Gen. Psychiatr. 52, 258-266.
2. Allen RM and SJ Young (1978) Phencyclidine-induced psychosis. Am. J. Psychiatr. 135, 1081-1084.
3. Andreasen NC, S Arndt, R Alliger, D Miller and M Flaum (1995) Symptoms of schizophrenia, methods, meanings and mechanisms. Arch. Gen. Psychiatr. 52, 341-351.
4. 2A receptor genes. Lancet 346, 281-282.
5. Bagley J and B Moghaddam (1997) Temporal dynamics of gluta-mate efflux in the prefrontal cortex and in the hippocampus following repeated stress: Effects of pretreatment with saline or diazepam. Neuroscience 77, 65-73.
6. Beasley CL and GP Reynolds (1997) Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 24, 349-355.
7. Benes FM, J McSparren, ED Bird, JP SanGiovanni and SL Vincent (1991) Deficits in small interneurons in prefrontal and cingulate corticies of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatr. 48, 996-1001.
8. Benes FM, EW Kwok, SL Vincent and MS Todtenkopf (1998) A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatr. 44, 88-97.
9. Beninger RJ (1983) The role of dopamine in locomotor activity and learning. Brain Res. Rev. 6, 173-196.
10. Beninger RJ and TV Gerdjikov (2004) The role of signaling molecules in reward-related incentive learning. Neurotoxicity Res. 6, 91-104.
11. Beninger RJ and BL Hahn (1983) Pimozide blocks establishment but not expression of amphetamine-produced environment-specific conditioning. Science 220, 1304-1306.
12. Berridge KC and TE Robinson (1998) What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res. Rev. 28, 309-369.
13. Blackwood DHR and WJ Muir (2004) Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia. Neurotoxicity Res. 6, 35-42.
14. Blackwood DH, A Fordyce, MT Walker, DM St. Clair, DJ Porteous and WJ Muir (2001) Schizophrenia and affective disorders - cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes, clinical and P300 findings in a family. Am. J. Hum. Genet. 69, 428-433.
15. Blackwood DHR, DM St. Clair, WJ Muir and JC Duffy (1991) Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Arch. Gen. Psychiatr. 48, 899-909.
16. Brody SA and MA Geyer (2004) Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. Neurotoxicity Res. 6, 79-90.
17. Cannon TD, TG van Erp and DC Glahn (2002) Elucidating continuities and discontinuities between schizotypy ansd schizophrenia in the nervous system. Schizophr. Res. 54, 151-156.
18. Celada P, MV Puig, R Martin-Ruiz, JM Casanovas and F Artigas (2002) Control of the serotonergic system by the medial pre-frontal cortex: potential role in the etiology of PTSD and depressive disorders. Neurotoxicity Res. 4, 409-419.
19. Coyle JT, G Tsai and D Goff (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. NY Acad. Sci. 1003, 318-327.
20. Devon RS and DJ Porteous (1997) Physical mapping of a glutamate receptor gene in relation to a balanced translocation associated with schizophrenia in a large Scottish family. Psychiatr. Genetics 7, 165-169.
21. Eysenck HJ and MW Eysenck (1985) Personality and Individual Differences. A Natural Science Approach (Plenum Press: New York, NY).
22. Fanous AH and KS Kendler (2004) The genetic relationship of personality to major depression and schizophrenia. Neurotoxicity Res. 6, 43-50.
23. Fanous AH, CO Gardner, CA Prescott, R Cancro and KS Kendler (2002) Nerotocism, major depression ands gender: A population-based twin study. Psychol. Med. 32, 710-728.
24. Freeman AS and BS Bunney (1984) The effects of phencyclidine and N-allynomethazocine on midbrain dopamine neuronal activity. Eur. J. Pharmacol. 104, 287-293.
25. French ED, C Pilapil and R Quirion (1985) Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system. Eur. J. Pharmacol. 116, 1-9.
26. Geyer MA, NR Swerdlow, RS Mansbach and DL Braff (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bull. 25, 485-498.
27. Geyer MA, K Krebs-Thomson, DL Braff and NR Swerdlow (2001) Pharmacological studies of prepulse inhibition models of senso-rimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology 156, 117-154.
28. Javitt DC and SR Zukin (1991) Recent advances in the phencycli-dine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
29. Jentsch JD and RH Roth (1999) The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacol. 20, 201-225.
30. Jentsch JD, A Tran, A Le, KD Youngren and RH Roth (1997) Sub-chronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17, 92-99.
31. Kandel E (2001) The molecular biology of memory storage: A dialogue between genes and synapses. Science 294, 1030-1038.
32. Kapur S (2003) Psychosis as a state of aberant salience: A framework linking biology, phenomonology, and pharmacology in schizophrenia. Am. J. Psychiatry 160, 13-23.
33. Kelley AE and KC Berridge (2002) The neuroscience of natural rewards: relevance to addictive drugs. [comment]. J. Neurosci. 22, 3306-3311.
34. Kendler KS and SR Diehl (1993) The genetics of schizophrenia: A current, genetic-epidemiologic perspective. Schizophr. Bull. 19, 261-285.
35. Kendler KS, M McGuire, AM Gruenberg, A O'Hare, M Spellman and D Walsh (1993) The Roscommon family study. III. Schizophrenia-related personality disorders in relatives. Arch. Gen. Psychiatr. 50, 781-788.
36. Klein DF and J Stewart (2004) Genes and environment: Nosology and psychiatry. Neurotoxicity Res. 6, 11-16.
37. Konradi C and S Heckers (2003) Molecular aspects of glutamate dysregulation: Implications for schizophrenia and its treatment. Pharmacol. Ther. 97, 153-179.
38. Krystal JH, DC D'Souza, D Mathalon, E Perry, A Belger and R Hoffman (2003) NMDA receptor antagonist effects, cortical glu-tamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology 169, 215-233.
39. 3 receptor agonist in schizophrenia. Eur. Neuropsychopharmacol. 13 Suppl. 4, S167-S168.
40. 3 receptor. Neurotoxicity Res. 6, 63-72.
41. Liddle PF (1987) The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br. J. Psychiatry 151, 145-151.
42. Liebowitz MR, FM Quitkin, JW Stewart, PJ McGrath, WM Harrison, JS Markowitz, JG Rabkin, E Tricamo, DM Goetz and DF Klein (1988) Antidepressant specificity in atypical depression. Arch. Gen. Psychiatr. 45, 129-137.
43. Lipska BK and DR Weinberger (2002) A neurodevelopmental model of schizophrenia: Neonatal disconnection of the hippocampus. Neurotoxicity Res. 4, 469-475.
44. Lipska BK, DN Lerman, ZZ Khaing, CS Weickert and DR Weinberger (2003) Gene expression in dopamine and GABA systems in an animal model of schizophrenia: Effects of antipsy-chotic drugs. Eur. J. Neurosci. 18, 391-402.
45. Lowy M, L Gault and B Yammamato (1993) Adrenolectomy attenuates stress induced elevation in extracellular glutamate concentration in hippocampus. J. Neurosci. 61, 1957-1960.
46. Luby ED, JS Gottlieb and BD Cohen (1962) Model psychoses and schizophrenia. Am. J. Psychiatr. 119, 61-65.
47. Malhotra AK (2004) Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain. Neurotoxicity Res. 6, 51-56.
48. 2 receptor gene and clozapine response. Schizophr. Res. 36, 92-93.
49. Mansbach RS and MA Geyer (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2, 299-308.
50. Mata I, MJ Arranz, T Lai, D Mancama, J Arrondo, M Beperet, R Villavicencio, J Munro, S Osborne and RW Kerwin (2002) The serotonergic system influences individual's response to risperi-done. Am. J. Med. Genet. 114, 728.
51. Miller R, JR Wickens and RJ Beninger (1990) Dopamine D-1 and D-2 receptors in relation to reward and performance: A case for the D-1 receptor as a primary site of therapeutic action of neu-roleptic drugs. Prog. Neurobiol. 34, 143-183.
52. Miyoshi K, A Honda, K Baba, M Taniguchi, K Oono, T Fujita, S Kuroda, T Katayama and M Tohyama (2003) Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol. Psychiatr. 8, 685-694.
53. Moghaddam B (1993) Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: Comparison to hippocampus and basal ganglia. J. Neurosci. 60, 1650-1657.
54. Moghaddam B (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron 40, 881-884.
55. Moghaddam B and M Jackson (2004) Effect of stress on prefrontal cortex function. Neurotoxicity Res. 6, 73-78.
56. Morris JA, G Kandpal, L Ma and P Austin (2003) DISC1 (Disrupted in Schizophrenia 1) is a centrosome-associated protein that interacts with MAPT1A, MIPT3, ATF4/5 and NUDEL, regulation and loss of interaction with mutation. Hum. Mol. Genet. 12, 1591-1608.
57. Ohnuma T, SJ Augood, H Arai, PJ McKenna and PC Emson (1998) Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol. Brain Res. 56, 207-217.
58. Ozeki Y, T Tomodo, J Kleiderlein, A Kamiya, L Bord, K Fujii, M Okawa, N Yamada, ME Hatten, SH Snyder, CA Ross and A Sawa (2003) Disrupted-in-schizophrenia-1 (DISC-1), mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc. Natl. Acad. Sci. USA 100, 289-294.
59. Palomo T, RM Kostrzewa, T Archer and RJ Beninger (2002) Neurodevelopmental liabilities in schizophrenia and affective disorders. Neurotoxicity Res. 4, 397-408.
60. Pin JP and R Duvoisin (1T95) Review: Neurotransmitter receptors I: the metabotropic glutamate receptors: Structure and functions. Neuropharmacology 14, 1-26.
61. Powell SB and MA Geyer (2002) Developmental markers of psychiatric disorders as identified by sensorimotor gating. Neurotoxicity Res. 4, 489-502.
62. Quitkin FM, JW Stewart, PJ McGrath, MR Liebowitz, WM Harrison, E Tricamo, DF Klein, JG Rabkin, JS Markowitz and SG Wager (1988) Phenelzine versus imipramine in the treatment of probable atypical depression: Defining syndrome boundaries of selective MAOI responders. Am. J. Psychiatr. 145, 306-311.
63. Quitkin FM, PJ McGrath, JW Stewart, W Harrison, E Tricamo, SG Wager, K Ocepek-Welikson, E Nunes, JG Rabkin and DF Klein (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine: A replication. Arch. Gen. Psychiatr. 47, 935-941.
64. Rankin CH (2002) From gene to identified neuron to behaviour in Caenorhabditis elegans. Nature Rev. Genetics 3, 622-630.
65. Reynolds GP, ZJ Zhang and CL Beasley (2001) Neurochemical correlates of cortical GABAergic deficits in schizophrenia: Selective losses of calcium binding protein immunoreactivity. Brain Res. Bull. 55, 13-18.
66. 2C receptor polymorphism. Lancet 359, 2086-2087.
67. Reynolds GP, ZJ Zhang and XB Zhang (2003) Ploymorphism of the promotor region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am. J. Psychiatr. 160, 677-679.
68. Reynolds GP, Z Abdul-Monim, JC Neill and ZJ Zhang (2004) Calcium binding protein markers of GABA deficits in schizophrenia - post mortem studies and animal models. Neurotoxicity Res. 6, 57-62.
69. Riley BP (2004) Linkage studies of schizophrenia. Neurotoxicity Res. 6, 17-34.
70. Schwartz JC, J Diaz, C Pilon and P Sokoloff (2000) Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Rev. 31, 277-278.
71. Seeman P, T Lee, M Chau-Wong and K Wong (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
72. 2 receptor gene. Am. J. Psychiatr. 158, 802-804.
73. Snyder SH (1976) The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am. J. Psychiatr. 133, 197-202.
74. St. Clair D, D Blackwood, W Muir, A Carothers, M Walker, G Spowart, C Gosden and HJ Evans (1990) Association within a family of a balanced autosomal translocation with major mental illness. Lancet 336, 13-16.
75. Stewart JW, FM Quitkin, PJ McGrath and GE Bruder (1999) Do tricyclic responders have different brain laterality? J. Abnormal Psychol. 108, 707-710.
76. 1-like dopamine receptors. Psychopharmacology (Berl.) 144, 95-110.
77. 2 receptor polymorphism at the Taq1 locus and the therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 10, 335-341.
78. 2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 11, 545-550.
79. Van Praag HM (2002) Crossroads of corticotropin releasing hormone, corticosteroids and monoamines. About a biological interface between stress and depression. Neurotoxicity Res. 4, 531-555.
80. Waddell S and WG Quinn (2001) Flies, genes, and learning. Annu. Rev. Neurosci. 24, 1283-1309.
81. Weinberger DR (1995) Neurodevelopmental perspectives in schizophrenia, In Psychopharmacology: The Fourth Generation of Progress (Bloom FE and DJ Kupfer, Eds.) (Raven Press: New York, NY), pp 1171-1183.
82. Wickens J (1990) Striatal dopamine in motor activation and reward-mediated learning: Steps towards a unifying model. J. Neural Transm. 80, 9-31.
83. Yerkes RM and JD Dodson (1908) The relation of strength of stimulus to rapidity of habit-formation. J. Comp. Neurol. Psychol. 18, 459-482.
84. Zhang ZJ and GP Reynolds (2002) A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus of schizophrenia. Schizophr. Res. 55, 1-10.